GeneDx shares plunge 49% after missing earnings and cutting 2026 guidance, triggering investor lawsuit.

GeneDx Holdings Corp. shares fell over 49% after the company reported weaker-than-expected Q1 results and lowered its 2026 revenue guidance from $540-555 million to $475-490 million. The company also revealed a $31.3 million goodwill impairment related to its Fabric Genomics acquisition and disclosed lower-than-expected reimbursement rates. These developments led to a securities class action lawsuit alleging that GeneDx and its executives misled investors about the company's financial health and prospects. Investors who bought shares between April 16, 2025, and May 4, 2026, are encouraged to contact Faruqi & Faruqi LLP to discuss their legal options before the August 3, 2026 deadline to seek lead plaintiff status.